Clinical References

Here’s your one-stop source for viewing and downloading NOCITA® (bupivacaine liposome injectable suspension) white papers, recent clinical studies and more.

NOCITA Technical Monograph

The NOCITA®(bupivacaine liposome injectable suspension) technical monograph reviews current post-operative pain management approaches as well as the therapeutic overview of safety and efficacy of FDA-approved long-acting local anesthetic for use in dogs.

Comprehensive bibliography included.

Download PDF >

An Extended Release Local Anesthetic: Potential for Future Use in Veterinary Surgical Patients

One of the most effective means of preventing the transduction and transmission of acute and perioperative pain is through the use of local anesthetics. This paper will review the use of local anesthetics, particularly bupivacaine, in dogs and cats, and introduce a formulation of prolonged release bupivacaine that is in development for dogs and cats.

Download PDF >

Clinical Effectiveness Study and Results in Dogs

Pilot, randomized, placebo-controlled clinical field study to evaluate the effectiveness of bupivacaine liposome injectable suspension for the provision of post-surgical analgesia in dogs undergoing stifle surgery published in BMC Veterinary Research. 

Download PDF >

Safety Evaluation of EXPAREL® (DepoFoam® Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species Comparison

EXPAREL (bupivacaine extended-release liposome injection) (DepoFoam bupivacaine) is in development for prolonged postsurgical analgesia. Repeat-dose toxicity studies were conducted in rabbits and dogs to compare the potential local and systemic toxicities of EXPAREL and bupivacaine HCl (Bsol), and the reversibility of any effects.

Download PDF >

The Safety of Liposome Bupivacaine Following Various Routes of Administration in Animals

Local and/or regional analgesic techniques are principal components of many multimodal analgesic techniques. This report presents results from four preclinical studies evaluating safety and pharmacokinetics (PKs) of liposome bupivacaine following intravascular (intravenous [IV], intra-arterial [IA]), epidural, and intrathecal administration in dogs.

Download PDF >

Now Approved For Cats

NOCITA is now FDA-approved for use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy. Please see the full Prescribing Information for more detail.

Continuing Education

Complete an educational online course designed for Veterinarians and Veterinary Technicians to stay ahead of current trends and up-to-date on cutting-edge techniques.

Experience the Difference

“We began using Nocita on canine patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results.  The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively.  Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications.  Nocita has quickly become standard protocol for analgesia on our canine cruciate ligament stabilization procedures.” 

Veterinary Surgeon

Milwaukee WI

DOG INDICATION: For single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs only. Do not use in dogs younger than 5 months of age, that are pregnant, lactating or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

CAT INDICATION: For use as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use as a peripheral nerve block in cats only. Do not use in cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in cats may include elevated body temperature, infection or chewing/licking at the surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

Other therapeutics from Aratana

ENTYCE logo

Finally, appetite stimulation is in your control.

ENTYCE® (capromorelin oral solution) is the ONLY FDA-approved veterinary therapeutic designed to safely and effectively stimulate appetite in dogs. Administered orally once a day, ENTYCE is appropriate for treating inappetence caused by chronic and acute conditions.

VIEW WEBSITE

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.